Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Equity Income: 2019-2025

Historic Equity Income for Ultragenyx Pharmaceutical (RARE) over the last 6 years, with Sep 2025 value amounting to $678,000.

  • Ultragenyx Pharmaceutical's Equity Income changed negligibly% to $678,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.0 million, marking a year-over-year decrease of 144.62%. This contributed to the annual value of -$1.1 million for FY2024, which is 380.86% down from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Equity Income of $678,000 as of Q3 2025, which was up 7,633.33% from -$9,000 recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's Equity Income's 5-year high stood at $25.7 million during Q3 2021, with a 5-year trough of -$31.0 million in Q2 2021.
  • Moreover, its 3-year median value for Equity Income was -$9,000 (2025), whereas its average is -$18,727.
  • The largest annual percentage gain for Ultragenyx Pharmaceutical's Equity Income in the last 5 years was 1,221.56% (2024), contrasted with its biggest fall of 1,629.12% (2024).
  • Over the past 5 years, Ultragenyx Pharmaceutical's Equity Income (Quarterly) stood at -$16.1 million in 2021, then soared by 111.43% to $1.8 million in 2022, then increased by 2.66% to $1.9 million in 2023, then plummeted by 181.95% to -$1.5 million in 2024, then remained steady at $678,000 in 2025.
  • Its Equity Income stands at $678,000 for Q3 2025, versus -$9,000 for Q2 2025 and -$157,000 for Q1 2025.